anti-Angiotensin II Receptor-Associated Protein (AGTRAP) Antibodies

Human Angiotensin II Receptor-Associated Protein (AGTRAP) interaction partners

1. A role for AT1 receptor-associated proteins in blood pressure regulation

2. ATRAP, a directly interacting and functionally inhibiting molecule of AT1R (show AGTR1 Antibodies), plays a protective role against the development of systemic insulin (show INS Antibodies) resistance via regulatory effects on adipose tissue function.

3. The phosphatidylinositol transfer protein (show PITPNA Antibodies) RdgBbeta (show PITPNC1 Antibodies) binds 14-3-3 (show YWHAQ Antibodies) via its unstructured C-terminus, whereas its lipid-binding domain interacts with the integral membrane protein ATRAP (angiotensin II type I receptor-associated protein).

4. the GG genotype of the AGTRAP rs11121816 T/G single nucleotide polymorphism was associated with increased mortality in two cohorts of patients who had septic shock.

5. CSF (show CSF2 Antibodies) angiotensin II, ACE (show ACE Antibodies), and ACE2 (show ACE2 Antibodies) levels are decreased in neuromyelitis optica/NMO spectrum disorder patients with anti-AQP4 (show AQP4 Antibodies) antibody, reflecting severe destruction of perivascular astrocytes

6. Small interfering RNA significantly attenuates angiotensin II type 1 receptor (show AGTR1 Antibodies)-stimulated inositol phosphate formation.

7. cloned a new human gene cDNA that codes for a homolog of the murine Agtrap protein

8. isolation of a novel protein, ARAP1 (show ARAP1 Antibodies), which promotes recycling of angiotensin(1A) to the plasma membrane in HEK (show EPHA3 Antibodies)-293 cells

9. CAML (show CAMLG Antibodies) is an important signal transducer for the actions of Ang II (show AGT Antibodies) in regulating the calcineurin-NFAT (show NFATC1 Antibodies) pathway and the interaction of CAML (show CAMLG Antibodies) with ATRAP may mediate the Ang II (show AGT Antibodies) actions in vascular physiology

Mouse (Murine) Angiotensin II Receptor-Associated Protein (AGTRAP) interaction partners

1. Results presented in this study suggested that the enhancement in adipose ATRAP plays a protective role against the development of diet-induced visceral obesity and insulin (show INS Antibodies) resistance through improvement of adipose inflammation and function via the suppression of overactivation of adipose AT1R signaling.

2. Renal ATRAP downregulation is involved in the onset and progression of blood pressure elevation caused by renal mass reduction, and implicates ATRAP as a therapeutic target for hypertension in chronic kidney disease.

3. These results implied that AngII could effectively induce EpiCs to differentiate into vascular smooth muscle-like cells through the AT1 receptor.

4. ATRAP expression in brown adipose tissue does not influence the pathogenesis of dietary obesity or metabolic disorders.

5. Identify Atrap as a novel regulatory protein (show TGFB1 Antibodies) of the cardiac Ca(2+)-ATPase SERCA2a (show CA-P60A Antibodies). Suggest that Atrap enhances the activity of SERCA2a (show ATP2A2 Antibodies) and, consequently, facilitates ventricular relaxation.

6. These results suggest that increased formation of AT1R-P2Y6R (show P2RY6 Antibodies) heterodimers with age may increase the likelihood of hypertension induced by Ang II (show AGT Antibodies).

7. although erythropoiesis and blood pressure are negatively controlled through the AT1 receptor inhibition in vivo, the pathways involved are complex and distinct

8. Distal tubule-dominant enhancement of ATRAP inhibits pathological renal sodium reabsorption and blood pressure elevation in response to high salt loading.

9. AT1R knockout mice were less vulnerable to controlled cortical impact-induced injury.

10. The inhibition of degradation of angiotensin II type 1 receptor (show AGTR1 Antibodies)-associated protein (show BCAP31 Antibodies) (ATRAP) and inactivation of AT1R-mediated p38 MAPK (show MAPK14 Antibodies) and STAT3 (show STAT3 Antibodies) signaling pathways, are involved cardiac hypertrophy.